A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.
Mantle Cell Lymphoma|Diffuse Large B-cell Lymphoma|Follicular Lymphoma
DRUG: RD14-01 cell infusion
Dose-limiting toxicity, DLT, Up to 2 years|Maximum tolerable dose, MTD, Up to 2 years
This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.